Back to results
US 11,028,174 B1Granted
Bifunctional molecules targeting PD-L1 and TGF-β
AssigneeLepu Biopharma Co., Ltd.
InventorsWenci Gong, Yiwei Tou
Life of this patent
Estimating the term…
Abstract
Provided are anti-PD-L1 antibodies with superior activities in blocking the PD-1 and PD-L1 interactions. Also provided are multifunctional molecules that include the anti-PD-L1 antibodies or fragments thereof fused to an extracellular domain of human TGF-beta receptor type-2.
Claims16
A multifunctional molecule, comprising an anti-PD-L1 (programmed death-ligand 1) antibody or fragment thereof and an extracellular domain of human TGF-β RII (TGF-beta receptor type-2),
- wherein the anti-PD-L1 antibody or fragment thereof has specificity to the human PD-L1 protein and comprises a heavy chain variable region (VH) comprising a VH CDR1, a VH CDR2 and a VH CDR3, and a light chain variable region (VL) comprising a VL CDR1, a VL CDR2, and a VL CDR3,
- wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3, respectively, comprise the amino acid sequences of
- SEQ ID NO:13-18,
- wherein the human TGF-β RII extracellular domain comprises the amino acid sequence of SEQ ID NO:72 and is fused to the anti-PD-L1 antibody or fragment thereof.
1 more element
Dependencies are inferred from the claim text.